Edap Tms (EDAP) Rating Increased to Strong-Buy at Zacks Investment Research
Edap Tms (NASDAQ:EDAP) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday, Zacks.com reports. The firm currently has a $5.50 price target on the medical equipment provider’s stock. Zacks Investment Research‘s target price suggests a potential upside of 7.84% from the stock’s previous close.
According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “
A number of other research firms have also weighed in on EDAP. ValuEngine upgraded shares of Edap Tms from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. TheStreet upgraded shares of Edap Tms from a “d+” rating to a “c-” rating in a research report on Thursday, February 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $6.50 price objective on shares of Edap Tms in a research report on Wednesday, April 3rd.
Edap Tms (NASDAQ:EDAP) last posted its quarterly earnings data on Monday, April 1st. The medical equipment provider reported $0.04 earnings per share for the quarter. Edap Tms had a negative net margin of 0.93% and a positive return on equity of 3.77%. The firm had revenue of $15.11 million for the quarter, compared to analyst estimates of $11.74 million. As a group, equities analysts anticipate that Edap Tms will post 0.11 earnings per share for the current year.
A hedge fund recently bought a new stake in Edap Tms stock. Naples Global Advisors LLC acquired a new stake in Edap Tms SA (NASDAQ:EDAP) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 13,500 shares of the medical equipment provider’s stock, valued at approximately $31,000. 10.07% of the stock is owned by institutional investors and hedge funds.
About Edap Tms
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).
Recommended Story: QQQ ETF
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.